Singlera Raises $60 Million in A+ Round for Cancer Tests

Singlera Genomics raised $60 million in an A+ round to expand its portfolio of non-invasive genetic diagnostics for cancer. The company, which operates in La Jolla, California and Shanghai, bases its tests on proprietary technologies that analyze cell-free DNA. Singlera offers five products for cancer screening, diagnosis and personalized treatment. The funding was co-led by Green Pine Capital Partners and Prosperico Ventures with participation from new and existing investors UCF Medical Investment, Jointown Pharmaceutical Group and Lilly Asia Ventures. More details....

Share this with colleagues:

Original Article: Singlera Raises $60 Million in A+ Round for Cancer Tests

More From BioPortfolio on "Singlera Raises $60 Million in A+ Round for Cancer Tests"